HL
VERV

HeadInvest LLC’s Verve Therapeutics VERV Stock Holding History

HeadInvest LLC’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$225K – 215
2025
Q2 		$225K Buy
20,000
+10,000
+100% +$57K 0.05% 200
2025
Q1 		$45.7K Buy
+10,000
New +$67K 0.01% 234
2023
Q4 		– Sell
-100
Closed -$1.18K – 680
2023
Q3 		$1.18K Buy
+100
New +$1.61K ﹤0.01% 704

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HeadInvest LLC's VERV Position: Q3 2025 in Review

HeadInvest LLC sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 20,000 shares — an estimated $225K sold.

HeadInvest LLC first reported a position in VERV in Q3 2023 and held it in 3 quarters. The position peaked at $225K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • HeadInvest LLC reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HeadInvest LLC sold 20,000 Verve Therapeutics shares in Q3 2025, an estimated $225K.
  • HeadInvest LLC first reported a position in Verve Therapeutics in Q3 2023 and held it in 3 quarters.
  • HeadInvest LLC's Verve Therapeutics position peaked at $225K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on HeadInvest LLC's 13F filing for Q3 2025, filed 14 Nov 2025.